Now Genzyme plans to replicate this strategy with Fabrazyme and Aldurazyme, two drugs which target ultra-rare genetic diseases.

FORBES: Magazine Article

Genzyme splits revenue from Aldurazyme with BioMarin Pharmaceutical (nasdaq: BMRN - news - people ).

FORBES: Can Genzyme Defy Skeptics Again?

Genzyme wrote the book on making a profit on incredibly rare genetic diseases like MPS I, which Aldurazyme treats.

FORBES: BioMarin Gets Ready To Bloom

If this happens next year and Aldurazyme sells, the tiny company will be within tossing distance of breaking even.

FORBES: BioMarin Gets Ready To Bloom

For Price's plans to come to fruition, Aldurazyme, the newly approved drug, must also receive regulatory clearance in Europe, which is expected soon.

FORBES: BioMarin Gets Ready To Bloom

And it has had plenty of opportunity to interact with Genzyme: The two companies formed a joint venture to develop Aldurazyme, BioMarin's first approved drug.

FORBES: BioMarin Follows Genzyme's Playbook

Aldurazyme treats an estimated 3, 000 people suffering from mucopolysaccharidosis 1 (MPS1).

FORBES: Can Genzyme Defy Skeptics Again?

In April, it received approval from the U.S. Food and Drug Administration for not one but two drugs: Aldurazyme, a treatment for the rare genetic disorder MPS I that is co-marketed with Novato, Calif.

FORBES: Genzyme To Buy SangStat For $600 Million

But Aldurazyme alone won't be enough.

FORBES: Magazine Article